Immucell (ICCC) Earnings Report, Financial Results, Financial analysis

Immucell Corp narrowed third quarter of 2024 net loss per share of $-0.09 compare to net loss per share of $-0.18 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.20 realized in previous quarter.

*third quarter of 2024*
Earnings Per Share	Revenues
$ -0.09	$ 6 Mill
$+0.09	$+3M +97.5 %

Immucell's Revenue rose by 97.5 % in third quarter of 2024 (Sep 30 2024) year on year, to $6 million and advanced by 14.93 % sequentially.

Immucell is

More on ICCC's Income Statement

ICCC's NET INCOME

Immucell in the third quarter of 2024 recorded net loss of $-0.702 million, an improvement compare to net loss of $-1.380 million in II. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-1.532 million realized in previous quarter.

More on ICCC's Growth

Immucell Inventories
Inventories declined by -1 % to $7.46 million from II. Quarter a year ago, sequentially inventories rose by 2.2 %. ICCC's Cash flow In the third quarter of 2024 company's net cash flow was $2 million, capital expenditures grew by -0.708488-87.52%, to $0 millions compare to same quarter a year ago

More on ICCC's Cash flow Statement

Earnings quality

Immucell Corp does not pay out common stock dividend.

In trailing twelve-month period Immucell Corp payed $ -0.02 cash per share, on a free-cash flow basis .

Book value grew by 7.72 % sequentially to $3.23 per share.
Tangible Book value grew to $ 3.22 per share from $ 2.99.

Company issued 0.35 million shares or 4.54 % in Sep 30 2024.

• More on ICCC's Dividends

Market Capitalization (Millions)	38
Shares Outstanding (Millions)	8
Total Debt (Millions $)	11
Revenue (TTM) (Millions $)	23
Net Income (TTM) (Millions $)	-4
Cash Flow (TTM) (Millions $)	3
Capital Exp. (TTM) (Millions $)	-1
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	55

Earnings quality

Immucell Corp does not pay out common stock dividend.

In trailing twelve-month period Immucell Corp had negative $ -0.02 cash flow per share, on a free-cash flow basis .

Book value grew by 7.72 % sequentially to $3.23 per share.
Tangible Book value grew to $ 3.22 per share from $ 2.99.

Company issued 0.35 million shares or 4.54 % in Sep 30 2024.

• More on ICCC's Balance Sheets

Market Capitalization (Millions)	38
Shares Outstanding (Millions)	8
Total Debt (Millions $)	11
Revenue (TTM) (Millions $)	23
Net Income (TTM) (Millions $)	-4
Cash Flow (TTM) (Millions $)	3
Capital Exp. (TTM) (Millions $)	-1
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	55

Immucell Corp

ICCC's Financial Statements and Analysis

News about Immucell Corp Earnings

ICCC Records Impressive Surge of 9.818% in Revenue during Fiscal Q3 of 2023

Immucell Corp Faces Challenging Times as Revenue Plunges by Record-Breaking -21.171% in Q2 of 2023

Immucell Corp Struggles as Deficit Expands to $-0.30 and Revenue Plummets in First Quarter of 2023 Earnings Season